Managing urinary incontinence: what works?

References

• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4–20
   PubMed Web of Science ®Google Scholar
• Milsom I, Altman D, Cartwright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI). In Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 5th edn. Paris, France: Health Publication Ltd, 2013:15–107
   Google Scholar
• Giarenis I, Mastoroudes H, Srikrishna S, Robinson D, Cardozo L. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder? BJU Int 2013;112:501–7
   PubMed Web of Science ®Google Scholar
• Hannestad YS, Rortveit G, Sandvik H, Hunskaar S; Norwegian EPINCONT study. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of incontinence in the County of Nord-Trøndelag. J Clin Epidemiol 2000;53:1150–7
   PubMed Web of Science ®Google Scholar
• Cartwright R, Srikrishna S, Cardozo L, Robinson D. Validity and reliability of the patient’s perception of intensity of urgency scale in overactive bladder. BJU Int 2011;107:1612–17
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374–9
   PubMedGoogle Scholar
• Rosier PF, Giarenis I, Valentini FA, Wein A, Cardozo L. Do patients with symptoms and signs of lower urinary tract dysfunction need a urodynamic diagnosis? ICI-RS 2013. Neurourol Urodyn 2014;33:581–6
   PubMed Web of Science ®Google Scholar
• Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol 2005;174:187–9
   PubMed Web of Science ®Google Scholar
• Robinson D, Giarenis I, Cardozo L. You are what you eat: the impact of diet on overactive bladder and lower urinary tract symptoms. Maturitas 2014 June 17. Epub ahead of print
   Web of Science ®Google Scholar
• Subak LL, Wing R, West DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009;360:481–90
   PubMed Web of Science ®Google Scholar
• McGrother CW, Donaldson MM, Thompson J, Wagg A, Tincello DG, Manktelow BN. Etiology of overactive bladder: a diet and lifestyle model for diabetes and obesity in older women. Neurourol Urodyn 2012;31:487–95
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD001405
   Google Scholar
• Dumoulin C, Hay-Smith EJ, Mac Habée-Séguin G. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2014;5:CD005654
   Google Scholar
• Moore K, Dumoulin C, Bradley C, et al. Adult conservative management. In Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 5th edn. Paris, France: Health Publication Ltd, 2013:1101–228
   Google Scholar
• Hay-Smith EJ, Herderschee R, Dumoulin C, Herbison GP. Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2011;12: CD009508
   Google Scholar
• National Institute for Health and Care Excellence. Urinary Incontinence in women. (CG171). London: National Institute for Health and Care Excellence, 2013
   Google Scholar
• Vella M, Nellist E, Cardozo L, Mastoroudes H, Giarenis I, Duckett J. Does self-motivation improve success rates of pelvic floor muscle training in women with urinary incontinence in a secondary care setting? Int Urogynecol J 2013;24:1947–51
   Web of Science ®Google Scholar
• Herderschee R, Hay-Smith EJ, Herbison GP, Roovers JP, Heineman MJ. Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 2011;7:CD009252
   Google Scholar
• Herbison GP, Dean N. Weighted vaginal cones for urinary incontinence. Cochrane Database Syst Rev 2013;7:CD002114
   Google Scholar
• Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 2007;51:67–74
   PubMed Web of Science ®Google Scholar
• Vella M, Duckett J, Basu M. Duloxetine 1 year on: the long-term outcome of a cohort of women prescribed duloxetine. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:961–4
   PubMed Web of Science ®Google Scholar
• Labrie J, Berghmans BL, Fischer K, et al. Surgery versus physiotherapy for stress urinary incontinence. N Engl J Med 2013; 369:1124–33
   PubMed Web of Science ®Google Scholar
• Giarenis I, Cardozo L. What is the value of urodynamic studies before stress incontinence surgery? BJOG 2013;120:130–2
   PubMed Web of Science ®Google Scholar
• Bent AE. Stress urinary incontinence. In Rock JA, Jones HW, eds. Te Linde's Operative Gynaecology, 10th edn. Philadelphia: Lippincott Williams & Wilkins, 2008:942–59
   Google Scholar
• Rehman H, Bezerra CC, Bruschini H, Cody JD. Traditional suburethral sling operations for urinary incontinence in women. Cochrane Database Syst Rev 2011;1:CD001754
   Google Scholar
• Dmochowski R, Athanasiou S, Reid F, et al. Surgery for urinary incontinence in women. In Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 5th edn. Paris, France: Health Publication Ltd, 2013:1307–75
   Google Scholar
• Petros PE, Ulmsten UI. An integral theory of female urinary incontinence. Experimental and clinical considerations. Acta Obstet Gynecol Scand Suppl 1990;153:7–31
   PubMedGoogle Scholar
• Ulmsten U, Henriksson L, Johnson P, Varhos G. An ambulatory surgical procedure under local anesthesia for treatment of female urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1996;7:81–5
   PubMedGoogle Scholar
• Ogah J, Cody JD, Rogerson L. Minimally invasive synthetic suburethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev 2009;4:CD006375
   Google Scholar
• Frati A, Poncelet C, Madelenat P, Luton D, Ducarme G. Evolution of surgical operations for female for stress urinary incontinence in gynaecology departments of Parisian public hospitals between 2002 and 2006. Gynecol Obstet Fertil 2009;37:589–97
   PubMed Web of Science ®Google Scholar
• Madhuvrata P, Riad M, Ammembal MK, Agur W, Abdel-Fattah M. Systematic review and meta-analysis of “inside-out” versus “outside-in” transobturator tapes in management of stress urinary incontinence in women. Eur J Obstet Gynecol Reprod Biol 2012;162:1–10
   PubMed Web of Science ®Google Scholar
• Richter HE, Albo ME, Zyczynski HM, et al.; Urinary Incontinence Treatment Network. Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med 2010; 362:2066–76
   PubMed Web of Science ®Google Scholar
• Schierlitz L, Dwyer PL, Rosamilia A, et al. Three year follow-up of tension-free vaginal tape compared with transobturator tape in women with stress urinary incontinence and intrinsic sphincter deficiency. Obstet Gynecol 2012;119:321–7
   PubMed Web of Science ®Google Scholar
• Abdel-Fattah M, Ford JA, Lim CP, Madhuvrata P. Single-incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: a meta-analysis of effectiveness and complications. Eur Urol 2011;60:468–80
   PubMed Web of Science ®Google Scholar
• Mostafa A, Lim CP, Hopper L, Madhuvrata P, Abdel-Fattah M. Single-incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: an updated systematic review and meta-analysis of effectiveness and complications. Eur Urol 2014;65:402–27
   PubMed Web of Science ®Google Scholar
• Chapple CR, Wein AJ, Brubaker L, et al. Stress incontinence injection therapy: what is best for our patients? Eur Urol 2005; 48:552–65
   PubMed Web of Science ®Google Scholar
• Kirchin V, Page T, Keegan PE, Atiemo K, Cody JD, McClinton S. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2012;2:CD003881
   PubMedGoogle Scholar
• Bakali E, Buckley BS, Hilton P, Tincello DG. Treatment of recurrent stress urinary incontinence after failed minimally invasive synthetic suburethral tape surgery in women. Cochrane Database Syst Rev 2013;2:CD009407
   Google Scholar
• Giarenis I, Mastoroudes H, Cardozo L, Robinson D. What do we do when a midurethral tape fails? Rediscovery of open colposuspension as a salvage continence operation. Int Urogynecol J 2012;23:1117–22
   PubMed Web of Science ®Google Scholar
• Han JY, Moon KH, Park CM, Choo MS. Management of recurrent stress urinary incontinence after failed midurethral sling: tape tightening or repeat sling? Int Urogynecol J 2012;23: 1279–84
   Web of Science ®Google Scholar
• Stav K, Dwyer PL, Rosamilia A, et al. Repeat synthetic mid urethral sling procedure for women with recurrent stress urinary incontinence. J Urol 2010;183:241–6
   PubMed Web of Science ®Google Scholar
• Jeffcoate TNA, Francis WJA. Urgency incontinence in the female. Am J Obstet Gynecol 1966;94:604–18
   PubMed Web of Science ®Google Scholar
• Newman DK, Wein AJ. Office-based behavioral therapy for management of incontinence and other pelvic disorders. Urol Clin North Am 2013;40:613–35
   PubMed Web of Science ®Google Scholar
• Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012; 12:CD003193
   Google Scholar
• Yamaguchi O. Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 2010;29:112–15
   PubMed Web of Science ®Google Scholar
• Zacche MM, Giarenis I, Cardozo L. Phase II drugs that target cholinergic receptors for the treatment of overactive bladder. Expert Opin Investig Drugs 2014 Jun 5. Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543–62
   PubMed Web of Science ®Google Scholar
• Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
   Google Scholar
• Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388–95
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013;63:283–95
   PubMed Web of Science ®Google Scholar
• Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296–305
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 2014 Feb 19. Epub ahead of print
   Google Scholar
• Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011;18:962–6
   PubMed Web of Science ®Google Scholar
• Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn 2009;28:47–51
   PubMed Web of Science ®Google Scholar
• Lose G, Mattiasson A, Walter S, et al. Clinical experiences with desmopressin for long-term treatment of nocturia. J Urol 2004; 172:1021–5
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP. Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 2004;93:996–1000
   PubMed Web of Science ®Google Scholar
• Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006;25:105–9
   PubMed Web of Science ®Google Scholar
• Chapple C. Which preparation of Botulinum Toxin A should be used, where should it be injected, and how should its efficacy be assessed? Eur Urol 2012;61:936–8
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti V, et al. Efficacy and safety of onabotulinum toxin A for idiopathic overactive bladder: a double-blind, placebo controlled randomised dose ranging trial. J Urol 2010;184:2416–22
   PubMed Web of Science ®Google Scholar
• Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64: 249–56
   PubMed Web of Science ®Google Scholar
• Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;12: CD005493
   Google Scholar
• Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012;61:834–9
   PubMed Web of Science ®Google Scholar
• Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. Neurourol Urodyn 2012;31: 1206–16
   PubMed Web of Science ®Google Scholar
• Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended release tolterodine: results from the overactive bladder innovative therapy trial. J Urol 2009;182:1055–61
   PubMed Web of Science ®Google Scholar
• van der Pal F, van Balken MR, Heesakkers JP, Debruyne FM, Bemelmans BL. Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 2006;97:547–50
   PubMed Web of Science ®Google Scholar
• Oerlemans DJ, van Kerrebroeck PE. Sacral nerve stimulation for neuromodulation of the lower urinary tract. Neurourol Urodyn 2008;27:28–33
   PubMed Web of Science ®Google Scholar
• Monga AK, Tracey MR, Subbaroyan. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. Int Urogynecol J 2012;23: 993–1005
   PubMed Web of Science ®Google Scholar
• Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol 2011;186:954–9
   PubMed Web of Science ®Google Scholar
• Al-Zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol 2011;185:981–6
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 2007;178: 2029–34
   PubMed Web of Science ®Google Scholar
• Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int 2011;109:1280–93
   PubMed Web of Science ®Google Scholar
• Gurocak S, De Grier RP, Feitz W. Bladder augmentation without integration of intact bowel segments: critical review and future perspectives. J Urol 2007;177:839–44
   PubMed Web of Science ®Google Scholar
• Fazili T, Bhat TR, Masood S, Palmer JH, Mufti GR. Fate of the leftover bladder after supravesical urinary diversion for benign disease. J Urol 2006;176:620–1
   PubMed Web of Science ®Google Scholar
• Niël-Weise BS, van den Broek PJ, da Silva EM, Silva LA. Urinary catheter policies for long-term bladder drainage. Cochrane Database Syst Rev 2012;8:CD004201
   PubMedGoogle Scholar